Member Info for EmeraldCarrots

22% up now.

Up 5%.

Up 18%. Bid?

Look at the facts!

Going for GDR. 5p a share would probably be it.

Exciting times!!!

Whatsoever with no major share holders AT ALL. Total and utter rubbish.

Raising £1,000,000. Nearly misssed that.

New investors if you ask me. Only existing share holders can take up the offer at 1.5p a share. Last time this happened the sp rocketed after........ more than doubled.

All IMHO.

By the looks. Offer for existing shareholders only @ 1.5p a share.

10.81% now.

+8%

Up 8%.

GULP!

Bliss Pharma want to find a new partner for BB-1701 conjugate (to attach to and carry poison directly to the tumour). Exiting cancer drug trial pilot study continuing I believe, but Eisai not going to partner Bliss going forward. They have financial woes I read. LOL - maybe they will partner Astrazeneca with it!! Anything is possible. Clearly Bliss think BB-1707 is a World class conjugate.

All IMHO.

Drug trial without Eisai, confirmed.

https://www.fiercebiotech.com/biotech/eisais-abandoned-enhertu-challenger-set-live-blissbio

Bliss Bio:-

https://www.blissbiopharma.com/Innovation?_l=en#Pipeline

No update on International sales of the Genedrive® MT-RNR1 since the Final results RNS of 29/11/2024.

This could be VERY good news. We will see in the half year report due any day.

From the final results:-

========================

Genedrive® MT-RNR1

· Initial orders of the Genedrive MT-RNR1 Products for new sites in the UK

· Initial overseas orders of the Genedrive® MT-RNR1 ID Kit !!!!!!!!!!!!!!!!!!!!

· Royal Sussex County Hospital, Brighton adopts the Genedrive® MT-RNR1 ID Kit for routine use

· Entered into a Clinical Trial Agreement with a leading multi-state physician organisation for clinical research studies of the Genedrive® MT-RNR1 Product Range in the US as part of planned FDA submission

· Breakthrough Device Designation received from the FDA

· NIHR and OLS Funding Package of c.£500k to address NICE Real World Evidence Generation Requirements for the Genedrive® MT-RNR1 ID Kit across 14 hospitals across the UK

· Positive value assessment by the Scottish Health Technology Group following referral by the Accelerated National Innovation Adoption pathway group in Scotland

No update on International sales of the Genedrive® MT-RNR1 since the Final results RNS of 29/11/2024.

This could be VERY good news. We will see in the half year report due any day.

========================

Genedrive® MT-RNR1

· Initial orders of the Genedrive MT-RNR1 Products for new sites in the UK

· Initial overseas orders of the Genedrive® MT-RNR1 ID Kit

Drug trial without Eisai, confirmed.

https://www.fiercebiotech.com/biotech/eisais-abandoned-enhertu-challenger-set-live-blissbio

Sales people at Genedrive have not sold a shed load of these internationally then frankly they need replacing with sales people that can. You could not ask for a better sales pitch. We will find out in the half year report due any day.

All IMHO.

"The exercise price for the Staff Share Options is £1.285". Not tomorrow then. LOL!